Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Meets Expectations

Curis (NASDAQ:CRIS – Get Rating) announced its earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17), RTT News reports. Curis had a negative net margin of 533.89% and a negative return on equity of 63.12%. During the same quarter in the previous year, the business posted ($0.12) EPS.

Curis Stock Up 1.1 %

Shares of NASDAQ CRIS traded up $0.01 during midday trading on Friday, reaching $1.00. 3,597,175 shares of the company’s stock traded hands, compared to its average volume of 1,529,752. The stock’s 50 day simple moving average is $1.03 and its 200-day simple moving average is $1.78. Curis has a one year low of $0.70 and a one year high of $9.04. The company has a market cap of $91.64 million, a price-to-earnings ratio of -1.61 and a beta of 2.66.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th.

Hedge Funds Weigh In On Curis

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Curis by 4.9% during the first quarter. BlackRock Inc. now owns 6,587,381 shares of the biotechnology company’s stock valued at $15,677,000 after purchasing an additional 306,340 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Curis by 0.9% during the first quarter. Vanguard Group Inc. now owns 4,241,608 shares of the biotechnology company’s stock valued at $10,095,000 after purchasing an additional 38,980 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in Curis by 3.6% in the first quarter. Nantahala Capital Management LLC now owns 2,478,265 shares of the biotechnology company’s stock valued at $5,898,000 after acquiring an additional 86,574 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Curis by 201.6% in the first quarter. Renaissance Technologies LLC now owns 1,318,200 shares of the biotechnology company’s stock valued at $3,137,000 after acquiring an additional 881,200 shares in the last quarter. Finally, Walleye Capital LLC boosted its stake in Curis by 3,036.1% in the first quarter. Walleye Capital LLC now owns 841,793 shares of the biotechnology company’s stock valued at $2,003,000 after acquiring an additional 814,951 shares in the last quarter. 78.15% of the stock is currently owned by institutional investors.

Curis Company Profile

(Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.